Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income growth accelerates

Q2 FY2026 operating income of $145.98M rose 31.1% year over year, ahead of the +7.2% change in trailing-twelve-month operating income. Sequentially, it rose 2.2% from the prior quarter.

Context

  • Operating income amounted to 14.0% of revenue in FY2025, up 5.1 pp from a year earlier.
  • Operating income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of $748.23M (+76.8%) for the fiscal year ending Dec 2026, a step up from the +69.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$145.98M+2.2% QoQ
Last fiscal yearDec 2025
$423.09M+69.7% YoY
LTMJun 2026
$403.24M+7.2% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.1%+151219.7%+151188.6 pp
1 year+69.7%+76.8%+7.2 pp
3-year CAGR—+34.0%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
423.09M USD
Year-over-year change
+69.7%
4-year CAGR
+29.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.2% is the 7th highest of 11, against a peer median of +83.3%.
  • Operating income amounts to 12.9% of revenue for AMRX, versus a peer median of 12.4%.
AMRX Competitors
Operating Income for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹29.56B INR-58.6%-5.1%8.9%
BHCBausch Health Companies Inc.LTM Jun 2026$2.76B USD+69.9%+68.8%25.4%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$1.98B USD+121.8%—11.5%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$518M USD+117.6%—38.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$403.24M USD+7.2%—12.9%
PRGOPerrigo Company plcLTM Jun 2026$215M USD-25.1%+63.3%5.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$123.61M USD+1811.6%—13.4%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$116.74M USD-40.0%+9.3%16.2%
EBSEmergent BioSolutions Inc.LTM Mar 2026$71.2M USD+171.3%—10.5%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-$7.21M USD-120.5%—17.2%
VTRSViatris Inc.LTM Jun 2026-$87.3M USD+96.6%—0.6%
Peer median (excluding AMRX) —+83.3%+36.3%12.4%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.